Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2015, Pages

  Klupp, Nerida L ^a   Chang, Dennis ^a   Hawke, Fiona ^b   Kiat, Hosen ^c   Cao, Huijuan ^d   Grant, Suzanne J ^a   Bensoussan, Alan ^a  

^a WESTERN SYDNEY UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; GLUCOSE BLOOD LEVEL; GLUCOSYLATED HEMOGLOBIN A; GLYCOSYLATED HEMOGLOBIN;

BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG CAPSULE; DRUG EFFICACY; GANODERMA LUCIDUM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHIOCORDYCEPS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; METABOLISM; RISK FACTOR;

BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REISHI; RISK FACTORS;

EID: 84930216057     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007259.pub2     Document Type: Review

References (34)

1. Chu TT, Benzie IF, Lam CW, Fok BS, Lee KK, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. British Journal of Nutrition 2012;107:1017-27.
2. Gao YH, Lan J, Dai XH, Ye JX, Zhou SF. A phase I/II study of Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. International Journal of Medicinal Mushrooms 2004;6:33-9.
3. Gao YH, Chen GL, Dai XH, Ye JX, Zhou SF. A phase I/II study of Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms 2004;6(4):327-34.
4. Klupp NL, Bensoussan A, Kiat H, Hawke F, Chang D. Ganoderma lucidum for hyperglycaemia in persons with metabolic syndrome. Unpublished raw data 2014.
5. Wang CW, Tschen J SM, Sheu W HH. Ganoderma lucidum on metabolic control in type 2 diabetes subjects - a double blinded placebo control study. Journal of Internal Medicine of Taiwan 2008;19:54-60.
6. Jin HM, Zhang GP, Cao X, Zhang M, Long JJ, Luo BQ, et al. Treatment of hypertension by linzhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. Microcirculatory approach to Asian traditional medicine. Amsterdam: Elsevier, 1996:131-8.
7. Wachtel-Galor S, Tomlinson B, Benzie FF. Ganoderma lucidum ('Lingshi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. British Journal of Nutrition 2004;91:263-9.
8. Capewell S, Ford E, Croft J, Critchley J, Greenland K, Labarthe D. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bulletin of the World Health Organisation 2010;88:120-30.
9. Chang S, Buswell J. Ganoderma lucidum (Curt.:Fr.) P. Karst. (Aphyllophoromycetideae): a mushrooming medicinal mushroom. International Journal of Medicinal Mushrooms 1999;1:139-46.
10. Chang S-T, Miles P. Mushrooms: Cultivation, nutritional value, medicinal effect and environmental impact. 2nd Edition. Boca Raton, USA: CRC Press, 2000. [0-8493-1043-1]
11. Chen J, Chen T. Chinese medical herbology and pharmacology. California: Art of Medicine Press, 2004:883-5.
12. Fatmawati S, Shimizu K, Kondo R. Ganoderol B: a potent α-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum. Phytomedicine 2011;18:1053-5. [doi: 10.1016/j.phymed.2011.03.011]
13. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
14. Hikino H, Konno C, Mirin Y, Hayashi T. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit body. Planta Medica August;4:339-40.
15. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. New England Journal of Medicine 2007;356(3):213-5.
16. Huie C, Di X. Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences 2004;812(1-2):241-57.
17. Kanmatsuse K, Kajiwara N, Hayashi K, Shimogaichi S, Fukinbara I, Ishikawa H, et al. Studies on Ganoderma lucidum. I. Efficacy against hypertension and side effects. Journal of the Pharmaceutical Society of Japan 1985;105(10):942-7.
18. Komoda Y, Shimizu M, Sonoda Y, Sato Y. Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chemical and Pharmaceutical Bulletin 1989;37(2):531-3.
19. Lakshmi B, Ajith T, Sheena N, Gunapalan N, Janardhanan K. Anti-peroxidative, anti-inflammatory, and antimutagenic activities of ethanol extract of the mycelium of Ganoderma lucidum occurring in South India. Teratogenesis, carcinogenesis, and mutagenesis 2003;23(Suppl 1):85-97.
20. Lee S, Rhee H. Cardiovascular effects of mycelium extract of Ganoderma lucidum: Inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chemical and Pharmaceutical Bulletin 1990;38(5):1359-64.
21. McKenna D, Jones K, Hughes K. Reishi. Botanical medicines: The desk reference for major herbal supplements. 2nd Edition. Binghamton, New York: The Haworth Herbal Press, 2002:825-55.
22. Morigawa A, Kitabatake K, Fujimoto Y, Ikekawa N. Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum. Chemical and Pharmaceutical Bulletin 1986;34(7):3025-8.
23. Pearson T, Mensah G, Alexander R, Anderson J, Cannon R, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals for the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
24. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
25. Shimizu A, Yano T, Saito Y, Inada Y. Isolation of an inhibitor of platelet aggregation from a fungus, Ganoderma lucidum. Pharmaceutical Bulletin 1985;33(7):3012-5.
26. Tao J, Feng K-Y. Experimental and clinical studies on inhibitory effect of Ganoderma lucidum on platelet aggregation. Journal of Tongji Medical University 1990;10(4):240-3.
27. Teow S. Effective dosage of the extract of Ganoderma lucidum in the treatment of various ailments. In: Royse DJ editor(s). Mushroom Biology and Mushroom Products. Pennsylvania: Pennsylvania State University, 1996.
28. Tomoda M, Gonda R, Kasahara Y, Hikino H. Glycan structures of ganoderans B and C, hypoglycemic glycans of Ganoderma lucidum fruit bodies. Phytochemistry 1986;25(12):2817-20.
29. Wachtel-Galor S, Tomlinson B, Benzie I. Ganoderma lucidum ('Lingzhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation. British Journal of Nutrition 2004;91(2):263-9.
30. Wachtel-Galor S, Szeto Y, Tomlinson B, Benzie I. Ganoderma lucidum ('Lingzhi'): acute and short term biomarker response to supplementation. International Journal of Food Sciences and Nutrition 2004;55(1):75-83.
31. World Health Organization (WHO), World Heart Federation, World Stroke Organization: Mendis S, Puska P, Norving B, editors. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organisation, 2011.
32. Willard, T. Reishi mushroom: Herb of spiritual potency and medical wonder. Issaquah, Washington: Sylvan Press, 1990.
33. Yang B, Jeong S, Song C. Hypolipidemic effect of exo- and endo-biopolymers produced from submerged mycelial culture of Ganoderma lucidum in rats. Journal of Microbiology and Biotechnology 2002;12(6):872-7.
34. Zhang H, Lin Z. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacologica Sinica 2004;25(2):191-5.